Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Evaluation of Oritavancin Use at a Community Hospital.

Co D, Roebuck L, VanLandingham J.

Hosp Pharm. 2018 Jul;53(4):272-276. doi: 10.1177/0018578717746415. Epub 2017 Dec 4.

PMID:
30038448
2.

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.

Jensen IS, Wu E, Fan W, Lodise TP, Nicolau DP, Dufour S, Cyr PL, Sulham KA.

J Manag Care Spec Pharm. 2016 Jun;22(6):752-64. doi: 10.18553/jmcp.2016.22.6.752.

3.

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study.

Anastasio PJ, Wolthoff P, Galli A, Fan W.

Infect Dis Ther. 2017 Mar;6(1):115-128. doi: 10.1007/s40121-016-0145-7. Epub 2017 Jan 11.

4.

Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study.

Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, Manos P, Keech R, Singh R, Heller B, Bubnova N, O'Riordan W; SOLO II Investigators.

Clin Infect Dis. 2015 Jan 15;60(2):254-62. doi: 10.1093/cid/ciu778. Epub 2014 Oct 6.

PMID:
25294250
5.

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.

Lodise TP, Redell M, Armstrong SO, Sulham KA, Corey GR.

Open Forum Infect Dis. 2017 Jan 19;4(1):ofw274. doi: 10.1093/ofid/ofw274. eCollection 2017 Winter.

6.

Review of oritavancin for the treatment of acute bacterial skin and skin structure infections.

García Robles AA, López Briz E, Fraga Fuentes MD, Asensi Diez R, Sierra Sánchez JF.

Farm Hosp. 2018 Mar 1;42(2):73-81. doi: 10.7399/fh.10807.

7.

Single-dose oritavancin in the treatment of acute bacterial skin infections.

Corey GR, Kabler H, Mehra P, Gupta S, Overcash JS, Porwal A, Giordano P, Lucasti C, Perez A, Good S, Jiang H, Moeck G, O'Riordan W; SOLO I Investigators.

N Engl J Med. 2014 Jun 5;370(23):2180-90. doi: 10.1056/NEJMoa1310422.

8.

Multiple-Dose Oritavancin Evaluation in a Retrospective Cohort of Patients with Complicated Infections.

Schulz LT, Dworkin E, Dela-Pena J, Rose WE.

Pharmacotherapy. 2018 Jan;38(1):152-159. doi: 10.1002/phar.2057. Epub 2017 Dec 11.

PMID:
29121395
9.

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, Sulham KA.

Clin Drug Investig. 2016 Feb;36(2):157-68. doi: 10.1007/s40261-015-0365-8.

10.

Oritavancin for acute bacterial skin and skin structure infections.

Messina JA, Fowler VG Jr, Corey GR.

Expert Opin Pharmacother. 2015 May;16(7):1091-8. doi: 10.1517/14656566.2015.1026256. Epub 2015 Mar 24. Review.

11.

Oritavancin: a review in acute bacterial skin and skin structure infections.

Syed YY, Scott LJ.

Drugs. 2015 Nov;75(16):1891-902. doi: 10.1007/s40265-015-0478-7. Review.

PMID:
26464319
12.

Oritavancin, a single-dose, complete regimen, for the treatment of acute bacterial skin and skin structure infections.

Wu G, Truong J, Lee S, Elnadoury O, Kuan W, Abraham T, Wu A, Liu M.

Expert Rev Anti Infect Ther. 2015 Apr;13(4):409-16. doi: 10.1586/14787210.2015.1012498. Epub 2015 Feb 9. Review.

PMID:
25661747
13.

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections.

Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR.

Infect Dis Ther. 2017 Jun;6(2):277-289. doi: 10.1007/s40121-017-0156-z. Epub 2017 Apr 6.

14.
15.

Oritavancin: A Long-Half-Life Lipoglycopeptide.

Saravolatz LD, Stein GE.

Clin Infect Dis. 2015 Aug 15;61(4):627-32. doi: 10.1093/cid/civ311. Epub 2015 Apr 21. Review.

PMID:
25900171
16.

Oritavancin: a long-acting antibacterial lipoglycopeptide.

Kaasch AJ, Seifert H.

Future Microbiol. 2016 Jul;11:843-55. doi: 10.2217/fmb-2016-0003. Epub 2016 May 10.

PMID:
27161039
17.

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting.

Deck DH, Jordan JM, Holland TL, Fan W, Wikler MA, Sulham KA, Ralph Corey G.

Infect Dis Ther. 2016 Sep;5(3):353-61. doi: 10.1007/s40121-016-0119-9. Epub 2016 Jul 1. Erratum in: Infect Dis Ther. 2016 Sep;5(3):363-5.

18.

Oritavancin: an investigational lipoglycopeptide antibiotic.

Karaoui LR, El-Lababidi R, Chahine EB.

Am J Health Syst Pharm. 2013 Jan 1;70(1):23-33. doi: 10.2146/ajhp110572. Review.

PMID:
23261897
19.

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections.

Brade KD, Rybak JM, Rybak MJ.

Infect Dis Ther. 2016 Mar;5(1):1-15. doi: 10.1007/s40121-016-0103-4. Epub 2016 Feb 1. Review.

20.

Oritavancin: A Novel Lipoglycopeptide.

Mattox J, Belliveau P, Durand C.

Consult Pharm. 2016 Feb;31(2):86-95. doi: 10.4140/TCP.n.2016.86. Review.

PMID:
26842686

Supplemental Content

Support Center